Welcome to our dedicated page for DR REDDYS LABORATORIES SEC filings (Ticker: RDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DR REDDYS LABORATORIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DR REDDYS LABORATORIES's regulatory disclosures and financial reporting.
Dr. Reddy’s Laboratories Limited has submitted a Form 6-K to notify investors that it filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2026 with the U.S. Securities and Exchange Commission. The report contains annual consolidated financial statements prepared under International Financial Reporting Standards as issued by the International Accounting Standards Board. The Form 20-F is also available on the company’s website for public access.
Dr. Reddy’s Laboratories has filed its annual Form 20-F for the fiscal year ended March 31, 2026, prepared under IFRS as issued by the IASB. The company reports 834,656,970 equity shares outstanding at period end and American depositary shares listed on the NYSE under the symbol RDY.
The report outlines extensive risk factors, including dependence on successful development, approval and commercialization of generics, complex molecules and biosimilars, as well as stringent global regulatory oversight. It highlights geopolitical disruptions, particularly in Russia, Ukraine and the Middle East, supply-chain and manufacturing quality risks, cyber and data protection threats, evolving drug-pricing and reimbursement regimes in key markets, environmental and sustainability obligations, significant patent and product-liability exposure, tax and foreign-exchange uncertainties, and India-specific corporate, securities and labor law developments.
Dr. Reddy’s Laboratories Limited has furnished a Form 6-K providing its Annual Secretarial Compliance Report for the year ended March 31, 2026, under Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Independent practicing company secretaries examined the company’s records, stock exchange filings, website disclosures and applicable SEBI and listing regulations. They reported that the company complied with all examined SEBI regulations and related circulars and guidelines, with no deviations, fines or violations recorded during the review period.
The report notes that required SEBI-related policies are adopted and updated on time, the company maintains a functional website with accurate links, its directors are not disqualified, performance evaluations are conducted, related party transactions receive prior audit committee approval, and there were no SEBI or stock exchange actions or additional non-compliances during the year.
Dr. Reddy’s Laboratories Ltd. filed a Form 6-K to share a press release announcing that it has been invited to ring the Closing Bell® at the New York Stock Exchange to celebrate 25 years of its NYSE listing.
The ceremony will be held at the NYSE headquarters in New York City on May 29, 2026 at 4:00 pm EDT, and will be livestreamed on NYSE.com and the New York Stock Exchange YouTube channel. Senior management, independent directors, former directors and other officials of Dr. Reddy’s are expected to attend.
The company highlights its long-standing focus on affordable and innovative medicines, its global presence across key markets such as the USA, India, Russia & CIS, China, Brazil and Europe, and its early adoption of sustainability and ESG goals.
Dr. Reddy’s Laboratories Limited has furnished a Form 6-K as a foreign private issuer to provide investors with access to its latest communications. The filing transmits an exhibit containing the transcript of the earnings call for the quarter and financial year ended March 31, 2026.
The earnings call was conducted on May 12, 2026, and the full transcript has been made available on the company’s website via a specified weblink. The company notes this submission is made pursuant to Regulation 30 of India’s Listing Obligations and Disclosure Requirements, helping keep investors informed through publicly accessible call details.
Dr. Reddy’s Laboratories filed a Form 6-K to share its schedule of analyst and institutional investor meetings. The company’s management will attend a series of in-person group meetings at investor conferences organized by Elara Capital, Bank of America, Nomura and Investec.
Sessions are planned across multiple financial centers between May 20, 2026 and June 3, 2026, including Hong Kong, Singapore, Toronto, Boston, New York and Princeton, New Jersey. The company notes that this schedule may change if required by investors or the company.
Dr. Reddy’s Laboratories Ltd. has launched its generic Semaglutide Injection in Canada after receiving a Notice of Compliance from Health Canada on April 28, 2026. Canada is the first G7 country to grant market authorization for this product.
The once-weekly injection is indicated for adults with type 2 diabetes mellitus, to improve blood sugar control alongside diet and exercise. It is supplied as a sterile solution in pre-filled pens at 2 mg/pen and 4 mg/pen strengths, each at 1.34 mg/ml, delivering 0.25 mg, 0.5 mg, or 1 mg doses per injection.
The company highlights its established presence and market access in Canada and describes GLP-1 therapies, including semaglutide, as a key focus area. This Canadian launch follows a recent semaglutide introduction in India under the Obeda® brand and supports Dr. Reddy’s broader strategy to expand access to advanced, affordable diabetes treatments across multiple markets.
Dr. Reddy’s Laboratories reported softer FY26 results, with consolidated revenues of ₹335,933 million, up 3.2% year on year, but profit attributable to equity holders down to ₹42,850 million, a 24% decline. Full‑year gross margin fell to 52.8% from 58.5% and EBITDA margin to 22.8% from 28.3%.
Q4 FY26 was particularly weak: revenues were ₹75,162 million, down 11.6% year on year and 13.9% sequentially, with gross margin dropping to 44.8%. The company booked a ₹4,530 million Shelf Stock Adjustment on US lenalidomide, impairments of CAR‑T and Eftilagimod Alfa assets totaling about ₹2,277 million, and VAT‑related provisions of ₹1,141 million, alongside earlier VAT and New Labour Codes charges.
Despite these one‑offs, the core portfolio showed mixed trends. FY26 Global Generics revenues grew 3% to ₹299,033 million, driven by Emerging Markets (₹67,608 million, up 23%), India (₹62,186 million, up 16%) and Europe (₹55,501 million, up 55%), while North America declined 22% to ₹113,737 million on lower lenalidomide sales. The balance sheet remained strong, with equity of ₹380,457 million, a net cash surplus of ₹32,714 million and FY26 free cash flow of ₹16,888 million. The Board recommended a final dividend of ₹8 per share, scheduled a July 23, 2026 AGM, refreshed the Board with one re‑appointment and one new independent director, appointed Deloitte Haskins & Sells LLP as statutory auditors for five years, and elevated the India Generics head, Sandeep Khandelwal, to senior management.
Dr. Reddy’s Laboratories Limited filed a Form 6-K as a foreign private issuer to share access to its recent earnings call. The company provided an audio recording link for the earnings call held on May 12, 2026, covering the quarter ended March 31, 2026.
The intimation, signed by the Company Secretary and Compliance Officer, is addressed to multiple exchanges in India and the United States, indicating that the recording is available for information and record-keeping purposes for all listed venues.